Targeting potent warheads to the tumour microenvironment
The pre|CISION™ peptide drug conjugate platform. >
Avacta is seeking to expand its partnerships for targeted cancer therapies. >
Growing shareholder value by developing novel cancer therapies using our proprietary pre|CISION™ and Affimer® platforms. >
AVA6000 is the first clinical-stage pre|CISIONTM molecule. It is a peptide drug conjugate that leverages the tumour-specific expression of FAP.
Read more
Latest news
